Today Paradigm4 announced that Golden Seeds, one of the nation’s most-active, early-stage investment companies, has participated in the company’s Series A funding. Golden Seeds joins Sigma Partners and Kepha Partners who have backed Paradigm4 since its inception.

Golden Seeds focuses on investing in women-led companies. Paradigm4’s CEO is Marilyn Matz, She co-founded Paradigm4 with MIT Professor Michael Stonebraker, Turing Award winner, leading database researcher, and serial entrepreneur. Prior to Paradigm4, Marilyn co-founded the publicly traded Cognex Corporation.

Traction in Life Sciences attracts investment

Paradigm4 has shown traction in its two primary industry verticals: Life Sciences Informatics and Financial Markets. Paradigm4 counts among its Life Sciences customers industry leaders such as Novartis, Foundation Medicine, the National Institutes of Health, Agios, and Complete Genomics, a BGI company.

In the Financial Markets arena, the company has acquired customers in top proprietary trading firms and leading financial institutions such as PEAK6, PDQ, and Achievement Asset Management among others.

“At Golden Seeds, we believe that SciDB’s game-changing software is a substantial business opportunity under the experienced leadership team of Mike Stonebraker and Marilyn Matz,” noted Peggy Wallace, Managing Partner at Golden Seeds.

“SciDB’s proven ability to enable translational and precision medicine solutions, and our base of technology-leading customers, are a strong foundation on which to build. The Golden Seeds

investment will propel us to additional wins,” stated Marilyn Matz, CEO of Paradigm4. “We look forward to partnering with them to share in their collective expertise and network as we help researchers and data scientists pursue projects of unprecedented scale and scope.”